Anand Reddi is the Vice President of Global Strategic Initiatives and Corporate Operations at BeOne Medicines, a global oncology company. Prior to joining BeOne, he served on the executive committee at Adverum Biotechnologies as Vice President of Corporate Strategy, Corporate Affairs, and Investor Relations, where he focused on ocular gene therapy. From 2014 to 2021, Anand held various strategy and operations roles at Gilead Sciences, spanning medical affairs, emerging markets, corporate affairs, corporate strategy, global commercial product strategy and digital innovation. He was a member of the team that advanced Gilead’s generic voluntary licensing program, enabling access to HIV, viral hepatitis, and COVID-19 medicines in resource-limited settings—benefiting over 25 million patients across more than 130 countries. He also led the design and implementation of several of Gilead’s signature global health initiatives, including the world’s largest HIV Test & Treat program with the Vatican in Tanzania, and an innovative health financing and technology pilot for hepatitis C with MasterCard in Pakistan. Before to his tenure at Gilead, Anand was active in basic science cancer research, clinical research, and public health policy. His global health writings have been featured in The Huffington Post, The Washington Post, and The New York Times, with a primary focus on global HIV scale-up, including the President's Emergency Plan for AIDS Relief (PEPFAR). Mr. Reddi holds degrees from the University of Michigan and the University of Colorado School of Medicine. He was also a J. William Fulbright Scholar in South Africa. He has served on the board of directors of Hepion Pharmaceuticals and was a past board member of the Bay Area Global Health Alliance and the AIDS Healthcare Foundation.